Cargando…

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade

Activation of systemic immune responses using PD-1 checkpoint inhibitors is an essential approach to cancer therapy. Yet, the extent of benefit relative to risk of immune related adverse events (irAE) varies widely among patients. Here, we study endocrine irAE from 7 clinical trials across 6 cancers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Zia, Hammer, Christian, Carroll, Jonathan, Di Nucci, Flavia, Acosta, Sergio Ley, Maiya, Vidya, Bhangale, Tushar, Hunkapiller, Julie, Mellman, Ira, Albert, Matthew L., McCarthy, Mark I., Chandler, G. Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184890/ https://www.ncbi.nlm.nih.gov/pubmed/34099659 http://dx.doi.org/10.1038/s41467-021-23661-4

Ejemplares similares

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
por: Khan, Zia, et al.
Publicado: (2020)

Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy
por: Khan, Zia, et al.
Publicado: (2023)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro
por: Hammer, Christian, et al.
Publicado: (2022)

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
por: Khan, Zia, et al.
Publicado: (2019)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Immune Checkpoint Blockade Anti–PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome
por: Lanzolla, Giulia, et al.
Publicado: (2019)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection
por: Ou, Huilin, et al.
Publicado: (2022)

Relapsing Polychondritis following PD-1 Blockade by an Immune Checkpoint Inhibitor
por: Mutoh, Tomoyuki, et al.
Publicado: (2023)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
por: Schneider, Stephanie, et al.
Publicado: (2017)

Coming of Age: Human Genomics and the Cancer–Immune Set Point
por: Hammer, Christian, et al.
Publicado: (2022)

Identifying and mitigating batch effects in whole genome sequencing data
por: Tom, Jennifer A., et al.
Publicado: (2017)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint
por: Koopmans, Iris, et al.
Publicado: (2018)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Publicado: (2021)

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Koyama, Shohei, et al.
Publicado: (2016)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
por: Zhang, Fei, et al.
Publicado: (2017)

Molecular determinants of response to PD-L1 blockade across tumor types
por: Banchereau, Romain, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
Publicado: (2020)

Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer(1)
por: Tu, Megan M., et al.
Publicado: (2019)

Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration
por: Lim, Yoong Wearn, et al.
Publicado: (2018)

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
por: Wang, Ziming, et al.
Publicado: (2018)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
por: Kadam, Pournima, et al.
Publicado: (2020)

Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1
por: Li, Huifang, et al.
Publicado: (2022)

A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
por: Su, Xiaofan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltrf1dqa3m8tn4kbrdmvcbi14n